Sartorius AG VZO (SRT) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Sartorius AG VZO stock €42.50, price €227, that is 81.3% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range €145.17 – €811.10 · fair‑value band €19.99 – €69.09 · the €227.00 price screens above the €42.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Sartorius AG VZO O.N. in your weekly email
Every Wednesday you see whether Sartorius AG VZO O.N. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sartorius provides bioprocess solutions, and lab products and services worldwide.
Show moreShow less
The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products.
It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions.
The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
Stock analysis
Sartorius AG VZO (SRT) currently trades at €227.00, while our model-based Fair Value estimate is €42.50, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €49.35 per share, and 0 of the 24 models we run sit above the €227.00 price.
Bear case: the Dividend Discount group reads lowest at €7.03, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: €19.99 (bear) to €69.09 (bull), the price of €227.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Sartorius AG VZO O.N. reported revenue of €3.5B in FY2025 versus €3.4B in FY2021, a compound +0.6%/yr. Reported net income was €155M in FY2025, compounding −22.4%/yr from FY2021.
Key figures
Market cap €15.7B Large · P/E ratio 80.2 · P/S ratio 4.43 · EPS (TTM) €2.83 · Dividend yield 0.3% · Net margin 6.0% · Return on equity 7.9% · Return on assets (EBIT) 9.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 4% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −81%, SRT screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€7.03 to €123.40). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear€19.99Fair Value €42.50Bull€69.09
Price €227.00 · Downside -81.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€1.78 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2020 (pandemic). Over 10 years: +12.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.7%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.7% vs 4.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 18%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +36.8% a year for the price and +5.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Recurring bioprocessing consumables deliver stable margins as the core strength, while equipment sales tied to biotech funding and capacity builds create earnings volatility.
Main risk: Danaher via Cytiva and similar large players with broader portfolios could bundle offerings and use scale to win customers or pressure prices in single-use bioreactors and filtration.
Bull case: Sartorius could integrate its AI tools and continuous processing platforms more deeply with customers to raise switching costs and defend margins against larger rivals.
Bear case: If larger competitors bundle more aggressively or win validation in key drug master files, Sartorius could lose share in high-margin consumables and see sustained pressure on equipment orders.
Sartorius draws most of its growth from recurring bioprocessing consumables that deliver stable margins, yet its equipment sales still move with biotech funding and capacity builds. A recent tie-up with an AI specialist now adds early-stage developability services to its cell line offerings. Will these newer services smooth earnings more than the traditional mix leaves room for swings in one-time orders?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−81.3% · Bottom 25%
Profitability
Return on equity (12 months)7.9% · Above median
Return on assets2.4% · Below median
Net margin (12 months)8.9% · Above median
Operating margin (12 months)17.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)9.9% · Above median
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity1.18× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)80.2× · Priciest 25%
P/B6.50× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)7.14× · Priciest 25%
Price / free cash flow122.2× · Priciest 25%
EV/EBITDA30.8× · Priciest 25%
PEG0.77× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)50· sector 40
PAST (return on equity)31· sector 30
HEALTH (low debt)41· sector 96
DIVIDEND (yield)6· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sartorius AG VZO O.N. Fair Value". https://www.fairvalue-calculator.com/stock/SRT
Frequently asked questions
Is Sartorius AG VZO (SRT) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of €42.50 versus a price of €227.00, about 81% lower (overvalued).
What is the fair value of SRT?
Our model-based fair value for Sartorius AG VZO O.N. is €42.50 (as of Nov 2, 2026), built from audited fundamentals. The current price: €227.00.
What is the quality score of SRT?
Sartorius AG VZO O.N. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sartorius AG VZO (SRT)?
Our model-based price target is the fair value of €42.50 (as of Nov 2, 2026) from 24 valuation models. Cautious scenario €19.99, optimistic scenario €69.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Sartorius AG VZO O.N. stock forecast for 2026?
Our models put fair value at €42.50, about 81% lower versus a price of €227.00 (overvalued). Cautious scenario €19.99, optimistic scenario €69.09. The calculation is refreshed regularly with new filings.
What is the revenue of Sartorius AG VZO (SRT)?
Sartorius AG VZO O.N. reported trailing-twelve-month revenue of about €3.7B (latest available figure, as of Nov 2, 2026).
Does Sartorius AG VZO O.N. pay a dividend?
Sartorius AG VZO O.N. currently shows a dividend yield of 0.32% relative to its recent price (as of Nov 2, 2026).
What growth is priced into Sartorius AG VZO (SRT)?
For today's price to be fair in a discounted-cash-flow model, Sartorius AG VZO O.N. would have to grow free cash flow by +39.8 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.7 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of SRT use?
Our models discount Sartorius AG VZO O.N. at 10.0 %: a base by market capitalisation (large), damped by beta 1.45, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sartorius AG VZO O.N. that is +39.8 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Sartorius AG VZO (SRT) delivered so far?
Over the past 5 years revenue at Sartorius AG VZO O.N. grew +8.7 % a year. The price currently implies +39.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sartorius AG VZO (SRT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sartorius AG VZO O.N. (+39.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sartorius AG VZO (SRT)?
The free-cash-flow yield on the price is 1.37 %: that much free cash flow Sartorius AG VZO O.N. produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sartorius AG VZO (SRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sartorius AG VZO O.N. it is €42.50 per share (as of Nov 2, 2026), against a price of €227.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Sartorius AG VZO O.N. stock overvalued or undervalued in 2026?
As of Nov 2, 2026, SRT trades above its calculated fair value: price €227.00, fair value €42.50, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRT?
No. The price is what the market pays today (€227.00); the fair value is what the company's own numbers justify (€42.50). For Sartorius AG VZO O.N. the two are €184.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sartorius AG VZO O.N. worth?
The market values Sartorius AG VZO O.N. at about €15.7B (market capitalisation, as of Nov 2, 2026). Per share that is €227.00; our models calculate a fair value of €42.50 per share.
What do the bullish and bearish scenarios say about SRT?
Our models span a range for Sartorius AG VZO O.N.: cautious scenario €19.99, base €42.50, optimistic €69.09 per share (as of Nov 2, 2026, price €227.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SRT?
Sartorius AG VZO O.N. trades at a price-to-earnings ratio of 80.2 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €42.50 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 64.1. Other multiples: PEG 0.8, P/B 6.5, P/S 7.1, EV/EBITDA 30.8.
What is the PEG ratio of SRT?
The PEG ratio of Sartorius AG VZO O.N. is 0.77 (P/E divided by earnings growth, as of Nov 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Sartorius AG VZO (SRT)?
Balance-sheet figures for Sartorius AG VZO O.N. (as of Nov 2, 2026): return on equity 7.9%, debt of 1.18 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is SRT from its 52-week high?
Sartorius AG VZO O.N. trades at €227.00, about 4% below its 52-week high of €235.50 and 39% above the low of €163.49 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of €42.50 is for.
Which stocks are comparable to Sartorius AG VZO O.N.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sartorius AG VZO O.N. stock attractive at the current price?
The data as of Nov 2, 2026: price €227.00, calculated fair value €42.50 (−81%), Quality Score 49/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SRT calculated?
We run Sartorius AG VZO O.N. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €42.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Sartorius AG VZO O.N. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sartorius AG VZO (SRT)?
The closing price on Nov 5, 2026 was €227.00. Our model-based fair value is €42.50, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sartorius AG VZO O.N. right now?
The price sits above even our optimistic bull case (€69.09). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (€19.99 to €69.09). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Sartorius AG VZO (SRT) come from?
Earnings per share at Sartorius AG VZO O.N. grew +5.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +13.4 %, EBIT margin −1.3 %, tax rate −0.3 %, residual (interest, one-offs) −5.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sartorius AG VZO O.N.
How large is the market capitalisation of Sartorius AG VZO (SRT)?
The market capitalisation of Sartorius AG VZO O.N. is €15.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sartorius AG VZO (SRT)?
The price-to-sales ratio of Sartorius AG VZO O.N. is 4.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sartorius AG VZO (SRT)?
Earnings per share at Sartorius AG VZO O.N. are €2.83 (price ÷ EPS = P/E 80.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sartorius AG VZO (SRT)?
The dividend yield of Sartorius AG VZO O.N. is 0.3% (payout 25.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sartorius AG VZO (SRT)?
The net margin of Sartorius AG VZO O.N. is 6.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sartorius AG VZO (SRT)?
The return on equity (ROE) of Sartorius AG VZO O.N. is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sartorius AG VZO (SRT)?
On an EBIT basis the return on assets of Sartorius AG VZO O.N. is 9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sartorius AG VZO (SRT)?
The operating margin of Sartorius AG VZO O.N. is 17.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sartorius AG VZO (SRT)?
Revenue at Sartorius AG VZO O.N. is growing +9.9% versus a year earlier (3y avg −5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sartorius AG VZO (SRT)?
Earnings per share at Sartorius AG VZO O.N. are growing +239% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sartorius AG VZO (SRT) carry?
The net debt of Sartorius AG VZO O.N. is €3.9B (fiscal year 2025, ≈ 18.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sartorius AG VZO O.N. in the live analysis
One click puts Sartorius AG VZO O.N. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 2, 2026